Form 4: Aquestive Therapeutics Chief Science Officer Receives 10,000 Shares of Restricted Stock

Stephen Wargacki, Chief Science Officer of Aquestive Therapeutics, acquired 10,000 shares of restricted common stock on May 10, 2024, which will vest in three annual installments.

Summary

• Stephen Wargacki, the Chief Science Officer of Aquestive Therapeutics, Inc., reported a transaction involving the acquisition of 10,000 shares of common stock on May 10, 2024.
• The shares are restricted stock and will vest in three annual installments: 25% on the first installment, 25% on the second installment, and 50% on the third installment.
• Following this transaction, Wargacki's total holdings in Aquestive Therapeutics amount to 267,963 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing about stock ownership. The acquisition of shares by an executive is generally a positive sign, but the document itself is simply a factual report.

Positives

• The acquisition of shares by a key executive could be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure related to insider transactions and provides limited insight into broader industry trends. However, it does indicate continued investment by key personnel in the company.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it reflects confidence from a key executive.

Key Dates